Incyte (INCY) Tops Q3 EPS by 46c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Tops Q3 EPS by 46c

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 2, 2021 7:00 AM EDT

Total product and royalty revenues of $778 million in Q3 2021 (+25% vs. Q3 2020); Jakafi® (ruxolitinib) revenues of $547 million in Q3 2021 (+12% vs. Q3 2020) Three regulatory approvals including OpzeluraTM (ruxolitinib) cream in the U.S. for the treatment of atopic dermatitis, Jakafi in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) and Minjuvi® (tafasitamab) in Europe for the treatment of relapsed or refractory DLBCL Pivotal TRuE-V data presentation at EADV highlighted significant improvements in facial and total body repigmentation in vitiligo patients treated with ruxolitinib cream; Company pursuing regulatory... More